热门资讯> 正文
InterCure报告1H结果
2024-08-30 21:09
- InterCure press release (NASDAQ:INCR): 1H Revenue of 126M New Israeli Shekels (NIS)
- Adjusted EBITDA for the six months ending June 30, 2024 was NIS 21M.
- The company's operating profit was NIS 11M.
- The October 7th terror attack effected the Company’s revenues in first half of 2024 due to damages to its southern facility located at Kibbutz Nir Oz.
- Expects double digit growth throughout the second half of 2024 compared to first half of 2024.
More on InterCure
- InterCure: A Cannabis Industry Leader Still Flying Under The Radar
- Financial information for InterCure
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
